title: Effects of phase III cardiac rehabilitation on mortality and cardiovascular events in elderly patients with stable coronary artery disease.
abstract: BACKGROUND
  Cardiac rehabilitation (CR) has numerous benefits, including reduction of mortality and cardiovascular events, in patients with coronary artery disease (CAD). However, the long-term effect of phase III CR in elderly patients with stable CAD is still unknown.
  
  
  RESULTS
  The 111 elderly male CAD patients (>or=65 years), including 37 subjects participating in supervised CR for 6 months and 74 age-matched controls, were analyzed. The patients were followed for up to 3,500 days, until the occurrence of death or 1 of the following major adverse cardiovascular events (MACE): cardiovascular death, acute coronary syndrome, refractory angina requiring revascularization, admission for congestive heart failure, or stroke. All-cause mortality tended to be lower in the CR group than in the Control group (14% vs 28%, P=0.081). The MACE incidence was significantly lower in the CR group than in the Control group (30% vs 62%, P=0.001). Multivariate Cox proportional hazard analysis showed that the MACE incidence was significantly lower in the CR group than in the Control group [adjusted hazard ratio 0.43 (95% confidence interval 0.20-0.91), P=0.027].
  
  
  CONCLUSIONS
  Phase III CR has the beneficial effect of reducing cardiovascular events even in elderly patients with stable CAD.
authors.affiliation: Department of Cardiovascular Medicine, Juntendo University School of Medicine.
authors.forename: Tomo
authors.initials: T
authors.lastname: Onishi
authors.forename: Kazunori
authors.initials: K
authors.lastname: Shimada
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Sato
authors.forename: Eriko
authors.initials: E
authors.lastname: Seki
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Satoshi
authors.initials: S
authors.lastname: Sunayama
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Ohmura
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Masaki
authors.forename: Miho
authors.initials: M
authors.lastname: Nishitani
authors.forename: Kosuke
authors.initials: K
authors.lastname: Fukao
authors.forename: Atsumi
authors.initials: A
authors.lastname: Kume
authors.forename: Takahiro
authors.initials: T
authors.lastname: Sumide
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mokuno
authors.forename: Hisashi
authors.initials: H
authors.lastname: Naito
authors.forename: Sachio
authors.initials: S
authors.lastname: Kawai
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Daida
mesh_terms: D054058:Acute Coronary Syndrome / Q000453:epidemiology* / Q000401:mortality; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D003324:Coronary Artery Disease / Q000097:blood / Q000534:rehabilitation*; D004032:Diet; D005081:Exercise Therapy; D005500:Follow-Up Studies; D006333:Heart Failure / Q000453:epidemiology* / Q000401:mortality; D006801:Humans; D015994:Incidence; D007564:Japan; D008055:Lipids / Q000097:blood; D008297:Male; D010353:Patient Education as Topic; D016016:Proportional Hazards Models; D020521:Stroke / Q000453:epidemiology* / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D008055:Lipids